Abstract | Knowledge of how the joint functions as an integrated unit in health and disease requires an understanding of the stromal cells populating the joint mesenchyme, including fibroblasts, tissue-resident macrophages and endothelial cells. Knowledge of the physiological and pathological mechanisms that involve joint mesenchymal stromal cells has begun to cast new light on why joint inflammation persists. The shared embryological origins of fibroblasts and endothelial cells might shape the behaviour of these cell types in diseased adult tissues. Cells of mesenchymal origin sustain inflammation in the synovial membrane and tendons by various mechanisms, and the important contribution of newly discovered fibroblast subtypes and their associated crosstalk with endothelial cells, tissue-resident macrophages and leukocytes is beginning to emerge. Knowledge of these mechanisms should help to shape the future therapeutic landscape and emphasizes the requirement for new strategies to address the pathogenic stroma and associated crosstalk between leukocytes and cells of mesenchymal origin.
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. Each disease is characterized by inflammation of the mesenchymal tissues that form the synovium, tendons, ligaments and joint capsule and, in some cases, structural damage to bone and cartilage. Inflammation of these tissues is broadly characterized by leuckocyte infiltration, fibroblast accumulation and neovascularization that supports cell expansion.
The term stroma was originally derived from the ancient Greek word describing a platform on which to lie and is used to describe the supporting substance of tis sues. Its principle role is to maintain the microenviron ment required by the parenchyma. The stroma comprises connective tissue, nerves, vessels, and the extracellular matrix (ECM) and fluids that the stromal cells produce 2 .
The soft tissues of the joint, including the synovium, cap sule, tendon and entheses, are predominantly composed of mesenchymal stromal cells.
In this Review, we first examine the pathophysiologi cal basis of inflammation and tissue damage with respect to the embryological origins of joint mesenchymal tis sues. We next discuss the stromal cell types that populate joint mesenchymal tissues, including fibroblasts, tissue resident macrophages (TRMs) and endothelial cells (vascular and lymphatic), and highlight their contri bution and functions in chronic synovial inflammation and tissue damage. Finally, we discuss potential future therapeutic strategies to target inflammation across joint mesenchymal tissues that address the pathogenic stroma and associated immune cell crosstalk.
Embryological origins of the joint
Inflammation and tissue damage are pivotal patholog ical processes that affect structures across the whole joint organ. To further understand the mechanisms and interrelationships underpinning these fundamental disease processes, it is important to consider the origins of joint tissues, given that an organ is best defined by its embryological origin as well as by its function. The embryological and anatomical origins of the tissues that comprise the joint might shape inflammation and tis sue damage, and knowledge of embryological processes can inform our understanding of disease patterns across the joint.
Although parts of the axial skeleton derive from the neural crest, the mesoderm is the precursor for mesen chymal tissues (Fig. 1) . Adult joint soft tissues are pre dominantly composed of cells of mesenchymal origin, including fibroblasts, vascular and lymphatic endothe lial cells and TRMs. Endothelial cells also originate from yolk sac derived erythro myeloid progenitor cells 3 . The embryological origins of stromal cells might shape the behaviour of these cell types in diseased adult tis sues. Notably, both mesoderm derived fibroblast and endothelial cell populations undergo sustained pheno typic changes after exposure to inflammatory stimuli, exhibiting stromal cell activation and a form of tissue memory known as stromal cell memory 4, 5 . However, the
Mesenchymal
Describes the embryonic connective tissue derived from the mesoderm; mesenchymal tissue includes the tissue of the musculoskeletal, circulatory and lymphatic systems.
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Stephanie G. Dakin 1, 2 , Mark Coles 2, 3 , Jonathan P. Sherlock 1, 2, 3 , Fiona Powrie 2, 3 distinct molecular markers expressed by these cell types vary, as discussed later in this Review. TRMs also exhibit complex activation states and a memory phenotype 6 . The origins and renewal of TRMs have been extensively reviewed elsewhere [7] [8] [9] [10] . Briefly, the majority of TRMs are established in their resident tissue locations during embryonic development and persist into adulthood, rather than being replaced from the pool of circulating adult monocytes 9, [11] [12] [13] [14] [15] [16] . Macrophages are first observed during early gestation and expand in the extra embryonic yolk sac during primitive haematopoiesis. Yolk sac derived haematopoietic stem cells (HSCs) emerge to form bone marrow precursor cells, which subsequently give rise to all immune cell lineages 9, 17 ( Fig. 1) . Importantly, yolk sac derived TRMs are phenotypically distinct from HSC derived progeny 12 .
The subspecialized adult tissue niches that TRMs occupy dictate the heterogeneous phenotype and functions of these cells in health and disease 18 .
Mesenchymal cells of the joint
Traditionally, the diversity of stromal cells, particularly fibroblasts, and their functions beyond space filling and ECM homeostasis have been underexplored in inflam mation. Mesenchymal tissues in the joint, including the synovium, entheses and tendons, undergo pheno typic changes as a consequence of inflammation [19] [20] [21] . These changes include molecular and structural altera tions to the ECM that affect the functional quality of the healed tissue 22 . Although discerning the cell type that initiates the pathological process is challenging, stromal cells populating these tissues clearly provide a niche that is conducive to sustaining chronic inflammation 4, 23, 24 . In the sections below, we focus exclusively on cells of mesenchymal origin, including fibroblasts, endothe lial cells and TRMs, rather than on haematopoietically derived cells, whose role in inflammation and damage has been well documented [25] [26] [27] .
Fibroblasts in the joint
Fibroblasts are the most abundant cell type populating the joint connective tissues 28 and synthesize the highly organized collagen rich scaffold that is necessary for joint structure and movement. Fibroblasts are defined by their spindle shaped morphology, the absence of specific lineage markers for leukocytes, endothelium and epithelium and by their ability to adhere to tissue culture plastic in vitro 29 . These cells probably arise from one of three distinct cellular origins: primary mesen chyme, local epithelial-mesenchymal transition or bone marrow derived precursors (circulating fibrocytes) 30, 31 . Fibroblasts can proliferate to generate new progeny, but the majority of fibroblasts probably originate from pri mary mesenchymal cells 32, 33 . In physiological conditions, fibroblasts produce ECM components (such as type I, type III and type V collagen and fibronectin) as well as factors that regulate ECM turnover, including matrix metalloproteinases (MMPs) and proteins involved in the formation of basement membranes (such as type IV collagen and laminin), thereby providing mechanical strength to tissues 34, 35 . Fibroblasts synthesize an array of paracrine factors 36 and have mechanosensitive prop erties 37 , which contribute to the functional adaptation of healthy joints. The intimate relationship between fibroblasts and mesenchymal stromal cells (MSCs), as well as the clinical use of MSCs to repair damaged tis sues, has resulted in a renewed interest in fibroblasts as therapeutic targets 28 .
Fibroblasts vary phenotypically and functionally at different anatomical sites and contribute to the iden tity of individual tissues, providing a so called stromal address code 33 . Rather than functioning as bystanders, fibroblasts are capable of actively participating in, and indeed orchestrating, inflammation and immunity 24, 38, 39 .
Fibroblast activation and memory. Fibroblast activation is a recognized feature of diseases that affect the joint, whereby fibroblasts adopt a pro inflammatory pheno type. This pathological feature has been identified in cancer 40 , rheumatoid arthritis 20, 21 and tendinopathy 19 . Fibroblast activation and memory span both innate and adaptive immune responses, suggesting that these processes are highly conserved disease mechanisms that are common to tissues of mesenchymal origin. A growing list of cell surface molecules and secreted products collectively make up a panel of fibroblast acti vation markers that are highly expressed under inflam matory conditions. These include CD90, CD44, CD55, vascular cell adhesion protein 1 (VCAM1; also known as CD106), uridine diphosphoglucose dehydrogenase, prolyl4hydroxylase, podoplanin (PDPN), endosia lin and fibroblast activation protein (FAP) 19, 24, 38, [41] [42] [43] . Fibroblast activation markers represent important pheno typic alterations that have been implicated in effecting the switch from resolving inflammation to persistent inflammation 43 .
Fibroblasts from different joint tissues maintain their phenotype, positional memory and topographic differentiation in culture ex vivo 44 . Fibroblasts isolated from rheumatoid arthritis (RA) synovium or diseased tendon have a stromal memory phenotype, whereby these cells show an increased capacity to respond to a repeated inflammatory stimulus 4, 19, 45 . Therefore, the sus tained expression of activation markers by fibroblasts in the joint reflects their primed status after exposure to an inflammatory stimulus. The biological mechanisms underpinning innate memory have been extensively reported for leukocytes 46, 47 and the occurrence of inflam matory memory in tissue resident cells of mesenchymal
Key points
• Joint inflammation and tissue damage are mediated by stromal cells of mesodermal origin.
• Stromal activation and memory of previous inflammatory insults are shared mechanisms exhibited by fibroblasts, tissue-resident macrophages and endothelial cells.
• Data characterizing the phenotype and function of cells of mesenchymal origin highlight the distinct fibroblast subtypes that mediate joint inflammation and tissue damage.
• Mesenchymal stromal cell niches and their interactions with leukocytes are implicated in the persistence of joint inflammation.
• For effective treatment of residual joint disease, strategies are needed that target the pathogenic stroma and associated immune cell crosstalk.
Parenchyma
The important functional elements of each body system.
Stromal cells
Non-haematopoietic, tissueresident cells.
Mesoderm
The middle embryonic primary germ layer that resides between the ectoderm and the endoderm.
Stromal cell activation
A process whereby stromal cells, including fibroblasts, tissue-resident macrophages and endothelial cells, adopt a pro-inflammatory phenotype and express distinct molecular markers after exposure to an inflammatory stimulus.
Stromal cell memory
A change in the capacity of stromal cells to respond to inflammatory stimuli that persists for future exposures.
Positional memory
Refers to the topographic memory of a cell across different tissues and joints, which for fibroblasts is regulated by homeobox (HOX) genes during development.
origin is gaining acceptance. Engagement of Toll like receptor 4 (TLR4) and downstream activation of the nuclear factor κB (NF κB) pathway is a prominent pathological feature of fibroblasts populating inflamed joint tissues 4, 19, 45 . Data suggest that fibroblast memory is associated with an altered responsiveness of NF κB to an inflammatory stimulus 48 . Given the longevity of tissue resident fibroblasts and the relatively low rates of cell turnover in the joint 49 , the effects of stromal memory in tissues such as the synovium and tendon are probably long lived. By contrast, dermal fibroblasts have high rates of turnover and do not exhibit a memory phenotype, suggesting that the occurrence of stromal memory might vary according to anatomical location 4, 50, 51 . Epigenetic changes are implicated in both fibroblast activation and memory. New insights into the epigenet ics of inflammatory rheumatic diseases in general have been reviewed in detail elsewhere 52 . Briefly, long term exposure of RA synovial fibroblasts to TNF reduces total histone H4 levels and promotes H4 acetylation 45 .
Chromatin accessibility can be increased by histone depletion or by histone acetylation, which weaken DNA-histone interactions. Data suggest that TNF exposure results in the removal of the chromatin bar rier from the CXCL10 promoter, thereby permitting abundant binding of NF κB family transcription fac tors and the recruitment of transcriptional machinery to this promoter (resulting in increased CXCL10 tran scription upon secondary inflammatory stimulation) 44 . Modifying the methylation status of DNA (such as by the addition or subtraction of methyl groups) is another important epigenetic modification that occurs in RA synovial fibroblasts during the early stages of disease 53 ; the activated and aggressive phenotype of RA synovial fibroblasts is associated with global DNA hypomethyla tion 54 . Although further studies are required to identify the mechanisms underpinning DNA methylation in RA, differentially methylated genes could be important prognostic biomarkers 53 . Finally, microRNAs (miR NAs), including miR29, might moderate the methy lation status of RA synovial fibroblasts; in one study, treatment of these cells with l methionine (a precursor of the methyl donor S adenosyl methionine) resulted in increased DNA methylation compared with treatment with betaine (a precursor of l methionine), which the investigators suggested might be because of the induc tion of miRNAs that target the expression of enzymes involved in DNA methylation 55 . Therefore miRNAs might selectively target mechanisms that regulate DNA methylation. Collectively these studies advance our understanding of how epigenetic changes are implicated in fibroblast activation and memory, informing future strategies to selectively target pathogenic fibroblasts.
Fibroblast diversity. Emerging data from the past dec ade have shown that tissue resident fibroblasts help to define the pattern of joints involved in RA 56, 57 . The concept of epigenetically driven anatomical diversity of synovial fibroblasts provides an attractive mechanism to explain the clinical observations that different types of arthritis affect distinct types of joint. For example, oste oarthritis (OA) and psoriatic arthritis often involve the distal interphalangeal joints, whereas RA is frequently symmetrical and more commonly affects the metacarpo phalangeal joints 58 . By contrast, ankylosing spondylitis mainly targets spinal ligaments and entheseal tissue 59 . This concept has prompted improved characterization of the phenotypes of fibroblast subsets and their different proposed functions. In RA, synovial fibroblasts undergo distinct changes in function, including a loss of immuno suppressive response in early disease, followed later by acquisition of an immunostimulatory phenotype 60 . Highly conserved homeobox (HOX) transcription factors specify the regional identity of cells and tissues throughout the body (conferring positional stromal memory) 61, 62 , and adult fibroblasts retain important fea tures of embryonic positional HOX gene expression 57 . Fibroblasts also vary according to their anatomical loca tion in relation to tissue structures at an individual site and the exogenous stimuli they receive 57, 58, 63 . Whether this variability can be attributed to the plasticity of indi vidual fibroblasts, which is necessary for responding to www.nature.com/nrrheum different environmental cues, and whether phenotypic variation can be used to define distinct fibroblast subsets specialized for different niches remain unclear.
The synovium is composed of fibroblasts in the lining and sublining that vary in terms of their phenotype and function. Single cell RNA sequencing and immunohis tochemistry data have revealed that RA synovial fibro blasts can be broadly characterized into three subsets: lining, immunoregulatory and pathogenic fibroblast populations (Fig. 2) . Fibroblasts of the synovial lining are Tissue damage
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Immunoregulatory fibroblast , express podoplanin (PDPN) and CD55 and release matrix metalloproteinase 1 (MMP1) and MMP13, which are implicated in tissue destruction. Immunoregulatory and pathogenic fibroblast subsets that predominantly occupy the synovial sublining exhibit a proliferative and pro-inflammatory phenotype. Immunoregulatory fibroblasts promote fibroblast accumulation and invasion. These cells express CD34 and release chemokines and cytokines, generating gradients that promote leukocyte retention. Pathogenic fibroblasts are a CD34 −
CD90
+ subpopulation that highly express markers of fibroblast activation and have inflammation 'memory'. Pathogenic fibroblasts express Toll-like receptor 4 (TLR4), which mediates the damage-sensing properties of these cells and downstream activation of the nuclear factor-κB (NF-κB) pathway via mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and Janus kinase (JAK)-STAT (signal transducer and activator of transcription) signalling pathways. These phenotypic features sustain the pro-inflammatory pathogenic phenotype of this fibroblast subset. Fibroblasts in the synovial sublining are in close proximity to activated endothelial cells (which express CD31, vascular cell adhesion protein 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1)) and CD68
+ tissue-resident macrophages (TRMs), which release pro-inflammatory mediators and proteases. CCL2, CC-chemokine ligand 2; CXCL12, CXC-chemokine ligand 12; FAP, fibroblast activation protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; PGE 2 , prostaglandin E 2 ; TGFβ, transforming growth factor-β; VEGF, vascular endothelial growth factor. (Fig. 2) .
The endolymphatic niche
Other mesenchymal stromal tissues, including the vas culature and lymphatics, contribute to sustained inflam mation of the joint organ. Neoangiogenesis is a prominent feature of arthritic joint tissues and can affect tissue architecture and pain perception 66 . In health, vascular endothelial cells control blood flow, vessel wall perme ability and leukocyte extravasation into tissues, thereby regulating the inflammatory process [67] [68] [69] [70] . In lymph nodes and tertiary lymphoid tissues, high endothelial vessels provide specialized microenvironments for effi cient entry of lymphocytes into tissues in an L selectin dependent process 71 . The phenotypes of endothelial cells change as inflammation transitions from an acute to a chronic process and also as activation of the innate immune system transitions to activation of the adaptive immune system 69 . Endothelial cell phenotypes are poorly characterized in tendon and entheseal tissues. However, in RA synovium, these cells can become activated, angi ogenic, apoptotic and leaky, which is analogous to many tumour microenvironments 72 . During long term expo sure to inflammatory stimuli, endothelial cells become activated, exhibit a memory phenotype and express adhesion molecules including intercellular adhesion molecule 1 (ICAM1), VCAM1 and CD31 (ReFs 5,73-75 ) (Fig. 2) . These activated endothelial cells also produce chemokines and promote leukocyte migration from the blood to local tissues 72 . Endothelial cell activation is a cause and a consequence of endothelial dysfunction 76, 77 , culminating in increased microvascular permeability, extravasation of plasma and joint oedema. Release of angiogenic factors, such as vascular endothelial growth factors (VEGFs), triggers angiogenesis to provide nec essary nutrients and oxygen to meet the metabolic demands of the inflamed tissue 78 . Importantly, neo angiogenesis further promotes the retention and survival of immune cells at inflamed sites, thereby sustaining chronic inflammation 39 . These angiogenic processes occur during normal inflammatory immune responses (such as following vaccination) 79 ; however, whether angiogenesis that occurs in joint disease is a cause or an effect of pathology remains unclear.
Stromal lymphatic vessels form a one way conduit for tissue fluid and leukocytes in health and disease 80 .
During adaptive immune responses, antigen presenting cells travel to lymph nodes via lymphatic vessels; these vessels express high levels of PDPN, which is also expressed by activated fibroblasts 81 . The permeability of lymphatic vessels is a tightly regulated dynamic process that alters during disease 82 . Lymphatic vessel growth (lymphangiogenesis) is a primary response during acute inflammation and becomes dysregulated in chronically inflamed adult tissues 83 . In experimental mouse mod els of inflammatory arthritis, lymph nodes and lym phatic vessels draining the diseased joint undergo an initial expansion phase to expedite lymphatic clearance. This expansion phase is followed by a collapse phase that is characterized by structural damage to lymphatic vessels and reduced lymphatic clearance 82, 84 . Alterations in lymphatic vessel function and lymph node volume also occur in patients with RA during a disease flare 85 . Therapies targeting aberrant lymphatic function have shown promise in preclinical models of inflammatory arthritis and might prove efficacious in RA 82 .
Tissue-resident macrophages
TRMs have a diverse range of biological functions. These cells are appropriately positioned and transcrip tionally primed to respond to local environmental chal lenges and maintain tissue homeostasis. TRMs mediate immune surveillance, induce inflammation and promote the subsequent resolution of inflammation 22, 86 . Given the biological complexity of these functions, TRM popula tions within a single tissue type are highly heterogene ous and contain diverse phenotypic and functionally distinct subtypes 7, 87 . In inflamed synovium, TRMs mediate immune sur veillance through the expression of a variety of pattern recognition receptors (PRRs), notably TLR2 and TLR4, and facilitate the recruitment of infiltrating leukocytes, including monocyte derived macrophages [88] [89] [90] . TRMs induce joint inflammation through the release of pro inflammatory mediators such as TNF, IL1β, IL6, granulocyte-macrophage colony stimulating factor (GM CSF) and prostaglandin E 2 (PGE 2 ), and drive fibroblast accumulation, angiogenesis, leukocyte recruitment and protease mediated tissue damage (Fig. 2) . Researchers have reported an essential function for non classical Ly6C lo monocytes in mouse models of arthritis 91 . The findings of this study revealed that Ly6C lo but not Ly6C hi mono cytes (classical monocytes) are crucial for the initiation of arthritis, and that Ly6C lo monocytes differentiate to inflammatory macrophages during disease. The investi gators suggested that synovial TRMs limit arthritis devel opment, and recruited macrophages differentiate from an M1 to an M2 phenotype in situ 91 . These findings high light the phenotypic heterogeneity of macrophages in the joint, demonstrating how macrophage activation status regulates disease progression and resolution. In support of this concept, synovial macrophages from patients with RA have distinct transcriptional profiles that are asso ciated with disease activity and response to therapy 92 . However, the distinction between TRMs and infiltrating macrophages is currently hampered by a lack of specific markers that distinguish between these populations in diseased human tissues.
Neoangiogenesis
The process by which new blood vessels develop by sprouting from existing vessels.
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TRMs are important regulators of repair and fibrosis across all tissue types 22 and are also implicated in mediat ing the resolution of inflammation. The pro inflammatory milieu in the inflamed synovium triggers an active pro cess of lipid mediator class switching and the subsequent release of families of specialized pro resolving mediators (SPMs). TRMs are a source of SPMs, including lipoxins, resolvins, protectins and maresins, which contribute to the resolution of inflammation 93, 94 . Collectively these lipid mediators initiate programmes that halt neutrophil infiltration, potentiate monocyte recruitment, moder ate vascular permeability and promote phagocytosis and drainage of apoptotic cells 94, 95 . The mechanisms involved in mediating resolution in inflammatory arthritis have been reviewed in detail elsewhere 96 . Distinct populations of resolution phase macrophages have been identified in mouse models of acute systemic inflammation; these macrophages expressed Alox15, Timd4 and Tgfb2, which are involved in the termination of leukocyte recruitment and the clearance of inflammatory cells 97 . However, the precise phenotypes of TRMs that mediate resolution in human joint disease requires further investigation.
Crosstalk between mesenchymal cells
Crosstalk between mesenchymal cell populations has an important function in sustaining inflamma tion. Damage sensing mechanisms and the release of cytokines and chemokines are pivotal pathological processes involved in the crosstalk between fibroblasts, endothelial cells, TRMs and leukocyte populations that sustain inflammation in the diseased joint 33, 98, 99 . RA synovial fibroblasts function as sentinel cells that can 'sense' tissue damage. This process occurs through the binding of these cells to damage associated molec ular patterns (DAMPs), including high mobility group protein B1 (HMGB1), heat shock proteins and S100 proteins via the PRRs TLR4 and receptor for advanced glycosylation end products (RAGE) [100] [101] [102] . Tenascin C, a matrix protein induced upon tissue damage, also trig gers inflammation by activating TLR4 in cells, including macrophages and synovial fibroblasts 103, 104 . Binding of these aforementioned DAMPs to TLR4 induces a high state of alert, which favours the development of chronic inflammation in multiple tissues 48, 105 . Engagement of TLR4 activates myeloid differentiation primary response protein 88 (MyD88) signalling pathways within synovial fibroblasts, thereby inducing pro inflammatory cytokine release via NF κB activation 48 . Consequently, activated synovial fibroblasts are primed to release a broad range of pro inflammatory mediators. These localized cytokine and chemokine gradients promote the migra tion, retention and survival of leukocytes and TRMs 43, 106 , creating a complex network that is conducive to sustain ing inflammation (Fig. 3) . The processes mediating leu kocyte trafficking between stromal compartments in RA have been reviewed in detail elsewhere 107 .
Fibroblast-immune cell crosstalk. RA synovial fibro blasts promote the retention of leukocytes in the joint through the release of cytokines and chemokines and through contact with other cells of mesenchymal ori gin. Pro inflammatory cytokines released by retained monocytes, T cells and TRMs, including IFNγ, TNF and IL1β, induce activated synovial fibroblasts to release high concentrations of PGE 2 , GM CSF and IL6, which exert differing effects on leukocytes. PGE 2 moderates chemokine production and promotes T helper 2 (T H 2) cell, T H 17 cell and regulatory T (T reg ) cell responses 108 . IL6 promotes the differentiation of CD4 + T cells towards T H 17 cells 109 , whereas GM CSF promotes neutrophil survival and monocyte differentiation in the inflamed synovium 33, 110 . The production of IL6 and other inflam matory cytokines and chemokines is regulated by a positive feedback loop (involving leukaemia inhibitory factor (LIF), LIF receptor and signal transducer and activator of transcription 4 (STAT4)) that selectively operates in fibroblasts 111 . Transforming growth factor β (TGFβ), which is present at high levels in RA synovium, is released from TRMs and synovial fibroblasts and induces persistent expression of CXCchemokine recep tor 4 (CXCR4) on synovial T cells, leading to the active retention of these cells through CXCL12, providing an additional mechanism for immune cell retention 112 . RA synovial fibroblasts also release a repertoire of chemok ines, generating a gradient consisting of CCL2, CCL4, CCL5, CCL8, CXCL8, CXCL12 and IFNβ 33, 113, 114 . This chemokine gradient actively promotes the recruitment, retention and survival of monocytes and CD4 + T cells at the inflamed synovial site (Fig. 3) . CXCL12, VCAM1 and IL6 have been identified as constitutive markers in fibroblastic reticular cells within lymphoid tissue and constitute part of a stromal address code, crucial for leukocyte survival and differentiation 33 .
Endothelial cell crosstalk.
Resident stromal cells pop ulating the inflamed synovium modulate the ability of endothelial cells to recruit leukocytes through the release of soluble mediators or through direct cell-cell contact. Stromal fibroblasts can modulate the ability of endothelial cells to recruit lymphocytes in a site specific manner. Fibroblasts from inflamed synovium can induce unstimulated human umbilical vein endothe lial cells (HUVECs) to bind to flowing lymphocytes 36 . In addition, stromal cells can modify the phenotype and responsiveness of endothelial cells, and hence their ability to recruit leukocytes 115 . Cytokine and chemok ine gradients mediate and sustain the crosstalk between endothelial cells, synovial fibroblasts and TRMs. For example, IL6, TGFβ and VEGFs released from TRMs provide the necessary cues to promote an angiogenic environment required to sustain endothelial cell activa tion and dysfunction (Fig. 3) . This concept is supported by findings showing that antibody neutralization of IL6 diminishes the ability of endothelial cells to bind lymphocytes in co cultures with RA synovial fibroblasts 36 . The RA synovial fibroblast milieu further sustains an angiogenic environment through the production of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5 and CXCL8 (ReF.
33 ) (Fig. 3) . RA fibroblasts regulate the expression of endothelial cell adhesion molecules, potentiate leuko cyte extravasation 60 and induce unstimulated HUVECs to bind lymphocytes in a CXCR4-CXCL12dependent manner 36 . Consequently, the interactions between cells of mesenchymal origin create and sustain an inflammatory milieu whereby synovial inflammation persists and potentially becomes independent of its inciting cause.
Function in tissue damage and repair
In health, repair mechanisms maintain the integrity of the soft tissues of the joints. In joint disease how ever, long term inflammation, tissue remodelling and fibrosis ensue, resulting in irreversible tissue damage. In contrast to normal adult tissues, human and murine fetal wounds and wounds in Nude (transcription factor FoxN1deficient) mice heal without scar formation 116 . Fetal wounds contain lower numbers of immune cells and lower levels of cytokines than wounds in adult tis sues [117] [118] [119] [120] . Differences between embryonic and adult tissue healing are also attributed to the milieu of pro fibrotic growth factors released by TRMs, including those of the TGFβ family. For example, TGFβ1 levels are lower in embryonic tissue undergoing repair than in adult tissue undergoing repair [121] [122] [123] . Other studies highlight differences in the production of MMP9 and MMP13 in the scarring process between fetal and adult fibroblasts 116 . The fact that fetal fibroblasts have a higher migration velocity and synthesize matrix proteins more quickly than adult fibroblasts, and that the turnover rates of col lagen, hyaluronic acid and ECM components are higher in fetal wound sites than in adult wound sites, suggests that rapid healing might also have a role in scarless tissue repair [124] [125] [126] . Such findings also suggest a reduced likeli hood of scarless tissue repair with ageing, accompanied by reduced efficiency of repair of tissues in the adult joint.
In adult tissues, fibroblasts and TRMs directly con tribute to joint destruction, bony erosions and bone remodelling through the production of enzymes such as MMPs 127 . MMP2, MMP9 and MMP13 are impli cated in the pathogenesis of RA and OA 128 . MMP9 is upregulated by CXCL12, a chemokine secreted by synovial fibroblasts in RA 129 . FAP is highly expressed within RA synovium and colocalizes with MMP13, where both FAP and MMP13 seem to promote tissue degradation via an unknown mechanism 130 . Cathepsins,
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Immune cells within synovium RA synovial fibroblasts also release chemokines, including CC-chemokine ligand 2 (CCL2), CCL4, CCL5, CCL8, CXCL8, CXCL12 and IFNβ, which promotes the recruitment, retention and survival of monocytes and CD4 + T cells. The production of IL-6, TGFβ and vascular endothelial growth factors (VEGFs) by TRMs promotes an angiogenic environment, which is required to sustain endothelial cell activation and dysfunction. The production of chemokines such as CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL8, IL-6 and VEGF by RA synovial fibroblasts further sustains an angiogenic environment. TRMs and synovial fibroblasts release tissue-damaging mediators including matrix metalloproteinases (MMPs) and TGFβ. Pro-inflammatory cytokines, including TNF, IL-1β, IL-6, PGE 2 and GM-CSF, released by TRMs induce activated synovial fibroblasts to release high concentrations of PGE 2 , GM-CSF and IL-6, which exert differing effects on leukocytes. TIMP, tissue inhibitor of metalloproteinase.
www.nature.com/nrrheum a major group of proteases involved in joint remod elling, are also upregulated in the diseased joint in both RA and OA 131 . Additionally fibroblasts can indi rectly contribute to tissue damage through crosstalk with TRMs and lymphocytes, further amplifying processes that drive tissue damage (Fig. 3) , while also presenting antigen to tissue infiltrating lymphoctyes 132 . Pathological conditions in which cells of mesenchy mal origin have a role include chronic inflammation (for example, RA and chronic skin wound healing), tissue fibrosis (for example, chronic obstructive pulmo nary disease (COPD)) and cancer (for example, breast cancer). Interestingly, although these diseases differ greatly in their aetiologies and genetic predispositions, they converge in terms of phenotype and function of the stromal component. Fibroblasts expand in the RA synovial tissue and in the tumour parenchyma, whereas fibrosis is characterized by profound changes in myofi broblast phenotype and function across different organs such as the lungs and kidneys 133 . Whether these features are intrinsic phenotypic properties that are acquired by fibroblasts as a consequence of exposure to chronic inflammation, or are derived from the conditioning of the pathogenic infiltrating cells is still under investiga tion and seems to differ in each condition 38 . Some data suggest that epigenetically programmed aggressive cells might 'spread' arthritis from inflamed to uninflamed joints in the early stages of disease 134 ; PDPN positive synovial lining fibroblasts from patients with RA are migratory and release cartilage destructive MMPs 21, 64 . Collectively, these data raise the possibility of distinct mesenchymal cell subsets being implicated in mediating the effects of tissue damage in the diseased joint.
Targeting mesenchymal cells
Given the important functions of mesenchymal cells, residual disease activity in patients treated with immune therapies might be attributable to stroma mediated inflammatory responses that are refractory to current ther apies that target immune cell populations 135 . New thera peutic approaches are therefore required to break the cycle and reset the system, particularly in scenarios in which inflammation becomes independent of the inciting stimu lus. Given the limited capacity of joint tissues to regenerate once damaged, substantial challenges are associated with curbing tissue damage, although such challenges might be addressed through moderating persistent inflammation. Future strategies are required to address the pathobiol ogy concerned with the stromal microenvironment, such as targeting cells of mesenchymal origin. A number of drugs that target stroma mediated processes in joint dis ease are already in clinical use or are being tested in early phase clinical trials, and a number of other upcoming strategies have potential for clinical application (TAble 1) .
Existing licensed therapies
NSAIDs and glucocorticoids provide symptomatic relief for a broad array of conditions, and can reduce both inflammation and pain. The clinical use of these therapies in the management of a multitude of diseases affecting the joint is well established [136] [137] [138] [139] . NSAIDs and glucocorticoids target fibroblasts, TRMs and endothelial cells via differing biological modes of action. The inhi bition of cyclooxygenase (COX) activity by NSAIDs dampens the release of prostaglandins, leukotrienes and thromboxane A 2 (ReF. 140 ). By contrast, glucocorti coids function via the glucocorticoid receptor to inhibit cytosolic phospholipase A2 (cPLA 2 ), regulate the expres sion of target genes of NF κB-mitogen activated pro tein kinase (MAPK) signalling and dampen the release of inflammation initiating eicosanoids 86 . Although NSAIDs and glucocorticoids continue to be prescribed as baseline anti inflammatory therapy for many rheu matic diseases, both of these therapies are associ ated with well documented adverse systemic effects. Importantly, COX2selective NSAIDs also dampen the protective responses controlling the resolution of inflammation 141, 142 , which might paradoxically impede the capacity of inflamed joint tissues to heal.
Monoclonal antibodies enable precise molecular targeting of cytokines, such as those that mediate joint inflammation. The biological modes of action and effi cacy of therapeutic inhibitors of IL1, IL6, TNF and IL17 in current clinical use are well reported (TAble 1) . One disadvantage associated with selective cytokine inhibition is the failure of this approach to fully target stroma mediated inflammatory responses and address the complex multidirectional crosstalk between mes enchymal cell populations and between mesenchymal populations and immune cells. Similarly, targeting chemokine gradients is an attractive strategy to moderate leukocyte retention 143 . However, chemokine antagonists, including the CXCR4targeting drug AMD3100, are associated with adverse systemic effects 144 and the pleth ora of chemokines that mediate stromal inflammatory responses presents a further therapeutic challenge.
Therapies in early-phase trials GM CSF, which is predominantly produced by acti vated T cells, monocytes and macrophages, is also released by tissue resident cells of mesenchymal origin including fibroblasts, TRMs and endothelial cells 145 . Humanized IgG1 monoclonal antibodies to GM CSF prevent the interaction of this cytokine with its receptor, GM CSFR, and hence reduce the downstream signal ling pathways of this receptor that converge on NF κB 146 . GM CSF has potential as a therapeutic target in auto immune and inflammatory disorders, including RA. Preclinical studies of therapies that target GM CSF or its receptor have shown encouraging results and have been reviewed in detail elsewhere 146 . A phase IIb study of mavrilimumab in 2018 demonstrated that long term treatment with this GM CSFR inhibitor maintained clinical responses (as assessed by disease activity score) and was well tolerated in patients with RA who had previously shown an inadequate response to DMARD therapy 147 . Further investigation is required to determine the efficacy of therapies that target GM CSF to modulate stroma mediated inflammatory responses in the joint.
Kinase inhibitors that target Janus kinase (JAK) or spleen tyrosine kinase (SYK) signalling pathways (and thereby block JAK-STAT signalling or MAPK-protein kinase C (PKC) signalling 148, 149 , respectively) have been investigated for their therapeutic utility to reduce 23, 169 ALX, formyl peptide receptor 2; CDK , cyclin-dependent kinase; COX, cyclooxygenase; cPL A2, cytosolic phospholipase A2; CXCL10, CXC-chemokine ligand 10; CYR61, cysteine-rich angiogenic inducer 61; GM-CSF, granulocyte-macrophage colony-stimulating factor ; GM-CSFR, GM-CSF receptor; DRV1, resolvin D1 receptor ; IL-1R, IL-1 receptor; IL-17R, IL-17 receptor; IL-6R, IL-6 receptor; JAK , Janus kinase; MAPK , mitogen-activated protein kinase; miRNA , microRNA ; MMP1, matrix metalloproteinase 1; NF-κB, nuclear factor-κB; PI3K , phosphatidylinositide 3-kinase; PDPN, podoplanin; PKC, protein kinase C; RA, rheumatoid arthritis; STAT, signal transducer and activator of transcription; SYK, spleen tyrosine kinase; TAK1, transforming growth factor-β-activated kinase 1; TGFβ, transforming growth factor-β; TNFR, TNF receptor; TRAF6, TNF receptor associated factor 6; TRM, tissue-resident macrophage TYK2, tyrosine kinase 2.
www.nature.com/nrrheum cytokine release (TAble 1) . Baricitinib, an oral reversi ble inhibitor of JAK1 and JAK2, has shown therapeu tic potential in the treatment of patients with RA. This treatment was associated with clinical improvements in patients with methotrexate refractory disease compared with treatment with placebo or with the anti TNF ther apy adalimumab 150 . However, protein kinase inhibitors can target a broad range of cell types, and off target adverse effects have been reported 151 , highlighting the importance of understanding the pharmacology of these drugs beyond the kinome.
Potential future strategies
In the cancer field, developments in therapies that tar get cancer associated fibroblasts populating the tumour stroma can inform on potential future strategies for tar geting the pathogenic stroma in rheumatic disease 152, 153 . Targeting the pathogenic stroma presents a considerable therapeutic challenge because of the biological complex ity underpinning the activation, memory and phenotypic diversity of mesenchymal cell populations. Potential future strategies to treat residual rheumatic disease might include targeting activated fibroblast subtypes, the use of epigenetic modifiers or the use of pro resolving mediators to target stroma mediated inflammation.
Selective targeting of the distinct fibroblast subtypes that mediate joint inflammation and tissue damage is one potential therapeutic approach. For example, cad herin 11 can regulate synovial fibroblast inflammation by synergizing with IL1β and TNF to regulate IL6 release 154 . Cadherin 11deficient mice have reduced lev els of inflammation compared with wild type mice in the K/B×N mouse model of arthritis, suggesting that cad herin expression regulates the inflammatory capacity of synovial fibroblasts. Notably, an anti cadherin 11 mon oclonal antibody also reduced the levels of inflammation in this model 154 . Cyclin dependent kinases (CDKs) reg ulate cell proliferation and survival and their inhibition, via specific inhibitors, and could potentially be used therapeutically to target fibroblast accumulation in RA synovium (TAble 1) . CDK pathways are also dysregulated in cancer, which has led to the development of drugs that inhibit these pathways, such as the CDK inhibitor ros covitine 155 . In synovial fibroblasts, IL6 and MMP1 pro duction is regulated by the CDK inhibitor p21 (ReF. 156 ).
Given that CD34 + CD90
− immunoregulatory fibroblasts are highly proliferative, invasive and produce IL6 (ReF. 64 ), repurposing roscovitine is a potential strategy for targeting this fibroblast subset in joint disease.
As discussed above, epigenetic changes are impli cated in mediating fibroblast activation and memory. Epigenetic alterations in RA synovial fibroblasts, includ ing alterations in DNA methylation, histone modifica tion and miRNA expression, are processes that could potentially be targeted therapeutically [52] [53] [54] [55] 157 (TAble 1) .
Moderating the epigenetic landscape is likely to have wide ranging effects on a variety of cell types, includ ing off target effects. Hence, the improvement of our understanding of the pharmacology of the drugs that target these processes, including understanding their effects beyond the epigenome, is essential before we can appreciate their potential utility to treat joint disease.
The roles of pro resolving mediators in joint health and disease are also becoming increasingly understood, and the use of pro resolving mediators or 'immuno resolvents' that moderate joint inflammation and promote tissue repair represents another potential ther apeutic strategy 96 . The biological modes of action of pro resolving mediators are well established from in vitro and in vivo studies and include limiting the infiltration of polymorphonuclear leukocytes, stimulating effero cytosis and activating endogenous tissue repair mecha nisms 93, [158] [159] [160] [161] [162] . Although pro resolving mediators target leukocytes, their biological actions are not associated with immunosuppression 86, 163 . Importantly, pro resolving mediators also target fibroblasts, TRMs and endothelial cells [164] [165] [166] and therefore possess the capacity to modulate stroma mediated inflammatory responses in joint tis sues (TAble 1) . Approaches for potentiating the processes that mediate resolution of inflammation include supple menting the diet with pro resolving mediator precursors, blocking the catabolism of pro resolving mediators and delivering stable analogues that bind to pro resolving receptors at the site of inflammation 86, 96 . For example, administration of the pro resolving mediator resolvin D3 (RvD3) can limit leukocyte infiltration and reduce lev els of eicosanoids at the paw joint in murine inflamma tory arthritis 167 . A metabolically stable epimer of RvD1, 17R RvD1, can attenuate arthritis severity, cachexia, paw oedema and leukocyte infiltration, as well as shorten the remission interval and protect against cartilage degrada tion, in murine models of acute inflammatory arthritis 168 . Data from in vitro studies also highlight the capacity of the pro resolving lipid mediator 15epi lipoxin A 4 (a metabolite of arachidonic acid) and maresin 1 (a metabolite of docosahexaenoic acid) to downregu late the IL1β induced expression of PDPN, STAT1 and IL6 in tendon derived stromal cells (from both healthy individuals and patients with chronic tendinopathy) 23, 169 . Collectively, these studies suggest that resolution based therapies might be an important future therapeutic option for addressing stromal pathobiology in the joint.
Conclusions
Stromal cells of mesenchymal origin including fibro blasts, TRMs and endothelial cells are pivotal popula tions that regulate health and disease in musculoskeletal tissues. New data are beginning to reveal the mecha nisms underpinning the activation and dysfunction of stromal cells of mesenchymal origin and their contribu tion to sustaining chronic joint inflammation. The dis covery that distinct synovial fibroblast subsets mediate joint inflammation and damage will inform precision therapeutic targeting of pathogenic stromal cell popu lations. These discoveries shape the future therapeu tic landscape, presenting exciting new approaches to address the pathogenic stromal microenvironment. Harnessing the capacity to modulate crosstalk between leukocyte and pathogenic stromal cell populations is a crucial barrier to overcome in the quest to advance therapeutic strategies for patients with refractory joint disease.
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